KIDS
OrthoPediatrics Corp. Common Stock
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
25.65
▼ 0.58 (2.21%)
MARKET · —
Price
Open
26.53
Prev close
26.23
Day high
26.23
Day low
25.24
Volume
257.63K
Market cap
$669.72M
P/E (TTM)
—
52W range
14.42 – 26.74
Trailing performance
Returnvs SPY
1W
+3.43%
+4.8%
1M
+37.02%
+33.3%
3M
+39.18%
+36.1%
6M
+51.24%
+40.2%
YTD
+44.43%
+32.1%
1Y
+31.67%
+11.7%
3Y
-33.12%
-107.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$669.72M
Enterprise value$735.02M
Revenue (TTM)$252.72M
Gross profit$186.14M
EBITDA$-445.00K
Net income$-39.73M
EPS (TTM)$-1.68
Free cash flow$3.19M
Total cash$45.88M
Total debt$111.18M
Book value / share$13.16
Shares outstanding26.11M
Float17.51M
Short % of float4.73%
Dividend yield—
Beta (5Y)0.97
Valuation & profitability ratios
Trailing P/E—
Forward P/E-36.13
PEG ratio—
Price / sales—
Price / book1.95
EV / revenue2.91
EV / EBITDA-1,651.73
Gross margin73.65%
Operating margin-5.77%
Profit margin-15.72%
Return on equity-11.36%
Return on assets-2.80%
Debt / equity32.36
Current ratio4.78
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $236.35M | $204.73M | $148.73M | $122.29M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$39.65M | -$37.82M | -$20.97M | $1.26M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$39.65M | -$37.82M | -$20.97M | $1.26M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.28 | -0.26 | +7.7% |
| Mar 2026 | -0.44 | -0.42 | +3.8% |
| Dec 2025 | -0.29 | -0.26 | +10.3% |
| Sep 2025 | -0.26 | -0.24 | +6.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.22 | 6 | $68.49M | +11.8% |
| Next quarter | -0.20 | 6 | $68.61M | +11.4% |
| Current year | -1.09 | 4 | $266.98M | +13.0% |
| Next year | -0.71 | 6 | $298.82M | +11.9% |
Analyst targets & ownership
Mean target$26.67
High target$35.00
Low target$22.00
Implied upside3.96%
Analyst count9
ConsensusNONE
Strong buy / Buy3 / 5
Hold1
Sell / Strong sell0 / 0
Held by insiders32.32%
Held by institutions65.92%
Institutions holding171
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+404.24K
Net buying
Buy transactions
15
462.41K shares
Sell transactions
5
58.17K shares
Net transactions
+20
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
8.44M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 9, 26 | RUF HAROLD Director |
STOCK | 11.44K | $0 | Direct |
| Jun 9, 26 | PELIZZON DAVID R Director |
STOCK | 11.44K | $0 | Direct |
| Jun 9, 26 | HUGHES BRYAN W Director |
STOCK | 11.44K | $0 | Direct |
| Jun 9, 26 | INFANTE MARIE C Director |
STOCK | 11.44K | $0 | Direct |
| Jun 9, 26 | MCDONALD JIMMY DUANE Director |
STOCK | 11.44K | $0 | Direct |
| Jun 9, 26 | DYER GEORGE SINCLAIR MITCHELL Director |
STOCK | 11.44K | $0 | Direct |
| Jun 9, 26 | FISCHER KELLY LAINE Director |
STOCK | 11.44K | $0 | Direct |
| Jun 9, 26 | THRODAHL MARK C Director |
STOCK | 11.44K | $0 | Direct |
| Jun 9, 26 | RICCITELLI SAMUEL D Director |
STOCK | 11.44K | $0 | Direct |
| Jun 9, 26 | BAILEY DAVID R Chief Executive Officer |
STOCK | 119.14K | $0 | Direct |
| May 13, 26 | GERRITZEN DANIEL J. General Counsel |
STOCK | 2.48K | $0 | Direct |
| Mar 16, 26 | HITE FRED L Chief Operating Officer |
SELL | 12.99K | $224.13K | Direct |
| Mar 16, 26 | BAILEY DAVID R Chief Executive Officer |
SELL | 19.54K | $336.98K | Direct |
| Mar 16, 26 | GERRITZEN DANIEL J. General Counsel |
SELL | 8.61K | $148.59K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAILEY DAVID R |
Chief Executive Officer | 417.16K | Stock Award(Grant) |
GERRITZEN DANIEL J. |
General Counsel | 147.05K | Stock Gift |
HAUSER JOSEPH W |
Officer | 194.77K | Sale |
HITE FRED L |
Chief Operating Officer | 277.48K | Sale |
HUGHES BRYAN W |
Director | 32.66K | Stock Award(Grant) |
ODLE GREGORY A |
Officer | 187.74K | Sale |
PELIZZON DAVID R |
Director | 6.95M | Stock Award(Grant) |
RICCITELLI SAMUEL D |
Director | 31.86K | Stock Award(Grant) |
RUF HAROLD |
Director | 41.48K | Stock Award(Grant) |
THRODAHL MARK C |
Director | 201.81K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
25.08
+2.28% from price
SMA 20
23.02
+11.43% from price
SMA 50
20.79
+23.37% from price
SMA 100
18.89
+35.79% from price
SMA 200
18.20
+40.93% from price
EMA 12
24.60
+4.25% from price
EMA 26
22.96
+11.72% from price
EMA 50
21.40
+19.85% from price
RSI (14)
72.4
Overbought
MACD (12,26,9)
1.64
Hist 0.25
ATR (14)
0.99
3.84% of price
Realised vol 30D
45.7%
Annualised
Bollinger upper
27.63
20, 2σ
Bollinger lower
18.41
20, 2σ
50 / 200 cross
Golden
20.79 vs 18.20
Trend bias
Above 200
+40.93%
Risk profile
Beta vs SPY
0.95
Less volatile than market
Correlation to SPY
0.27
Largely independent
Realised vol 30D
45.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-33.8%
Peak to trough
Max drawdown 5Y
-79.9%
Peak to trough
ATR 14
0.99
3.84% of price
Beta (reported)
0.97
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
20.00
-22.0% from spot
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
20.00
7 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
OrthoPediatrics Sees ‘Inflection Point’ as New Products Fuel Record Quarter
MarketBeat · 8d ago
OrthoPediatrics (KIDS) Q2 2026 Earnings Call Transcript
Motley Fool · 11d ago
OrthoPediatrics Corp. Q2 2026 Earnings Call Summary
Moby · 17d ago
Truist Adjusts Price Target on OrthoPediatrics to $22 From $20, Maintains Hold Rating
MT Newswires · 17d ago
OrthoPediatrics Corp (KIDS) (Q2 2026) Earnings Call Highlights: Record Revenue and EBITDA ...
GuruFocus.com · 18d ago
OrthoPediatrics Q2 Earnings Call Highlights
MarketBeat · 18d ago
OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 18d ago
OrthoPediatrics: Q2 Earnings Snapshot
Associated Press · 18d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.